当前位置: X-MOL 学术Mol. Ther. Methods Clin. Dev. › 论文详情
Successful Transduction with AAV Vectors After Selective Depletion of Anti-AAV Antibodies by Immunoadsorption.
Molecular Therapy - Methods & Clinical Development ( IF 4.875 ) Pub Date : 2020-01-21 , DOI: 10.1016/j.omtm.2020.01.004
Alejandro Orlowski; Michael G. Katz; Sarah M. Gubara; Anthony S. Fargnoli; Kenneth M. Fish; Thomas Weber

Gene Therapy with adeno-associated virus (AAV) based vectors shows great promise for the gene therapeutic treatment of a broad array of diseases. In fact, the treatment of genetic diseases with AAV vectors is currently the only in vivo gene therapy approach that is approved by the U.S. Food and Drug Administration (FDA). Unfortunately, pre-existing antibodies against AAV severely limit the patient population that can potentially benefit from AAV gene therapy, especially if the vector is delivered by intravenous injection. Here, we demonstrate that we can selectively deplete anti-AAV antibodies by hemapheresis combined with AAV9 particles coupled to Sepharose beads. In rats that underwent hemapheresis and immunoadsorption luciferase expression was dramatically increased in the hearts and fully restored in the livers of these rats. Importantly, our method can be readily adapted for the use in clinical AAV gene therapy.
更新日期:2020-01-21

 

全部期刊列表>>
化学/材料学中国作者研究精选
ACS材料视界
南京大学
自然科研论文编辑服务
剑桥大学-
中国科学院大学化学科学学院
南开大学化学院周其林
课题组网站
X-MOL
北京大学分子工程苏南研究院
华东师范大学分子机器及功能材料
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug